Helicobacter pylori is one of the main causes of digestive diseases, which isdifficult to treat and requires the administration of several antimicrobial agents. Considering the anti-inflammatory and antibacterial effect of atorvastatin, the present study aimed at adding this agent toa four-drug regimen in order to eradicate H. pylori.

A total of 220 patients with H. pylori infection were included in the current randomizedcontrolled clinical trial. In the current study, 110 patients in the control group received a 14-dayregimen of amoxicillin, clarithromycin, bismuth, and esomeprazole, and 110 patients in theintervention group received 40 mg of atorvastatin daily plus the antibiotic regimen for 14 weeks. Thetreatment results were evaluated 1 month later using H. pylori stool antigen test. Data were collectedusing checklist and analyzed using chi-squared and Fisher's exact tests with spss version 18.

Helicobacter pylori eradication rate in the intervention and control groups was 78.18% and65.45%, respectively (P = 0.025), and there was a significant difference in terms of non-ulcer dyspepsiabetween the groups (P = 0.049), but there was no significant difference in age, gender, and body massindex between the two groups (P < 0.05).

The present study results showed that adding atorvastatin to the four-drug regimen ofomeprazole, clarithromycin, bismuth, and amoxicillin is effective in the eradication of H. pylori. Also,the addition of atorvastatin to H. pylori eradication therapy is more effective in patients with non-ulcer dyspepsia.